Monitor for any further amendments or conversion to a 13D if Goldman Sachs increases its stake or changes investment intent. The current passive stake is minimal and unlikely to drive stock movement.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 9 $0.0400entry
- T+1 · 7d ago −56.50%α −56.13% · $0.0174
- T+5 · due 21h ago Pending
- T+5 · todayOpen
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Goldman Sachs filed an amended Schedule 13G disclosing a beneficial ownership of 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026. This is a routine passive stake update; the stake is very small relative to the company's market cap and represents no material change in investment intent.
Key Financial Metrics
Key Facts
- Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G
- Beneficial ownership: 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026
- Stake value approximately $203,129 based on filing data
- Filing is a routine passive stake update under Rule 13d-1(b)
Financial Impact
Stake of 203,129 shares (0.9%) valued at approximately $203,129
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000886982-26-000549 |
| Document: 0000886982-26-000549-index-headers.html | 0000886982-26-000549 |
| Document: 0000886982-26-000549-index.html | 0000886982-26-000549 |
| Document: 0000886982-26-000549.txt | 0000886982-26-000549 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Viewing Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers